Business
PEXA.B: Net loss deepens as PEXA pivots to diagnostics, seeking capital amid scientific progress
PEXA.B: Net loss deepens as PEXA pivots to diagnostics, seeking capital amid scientific progress
About this update from Pexa Ab Class B
PEXA AB reported a net loss of SEK 10.2 million for 2024, with declining sales and a strong focus on expanding its non-invasive lung diagnostics technology. The company faces significant funding needs and market risks but continues to advance scientific validation and global partnerships.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.